key: cord-0323043-14ptitsn
authors: Boucau, J.; Uddin, R.; Marino, C.; Regan, J.; Choudhary, M. C.; Flynn, J. P.; Chen, G.; Stuckwisch, A. M.; Mathews, J.; Liew, M. Y.; Singh, A.; Reynolds, Z.; Iyer, S. L.; Chamberlin, G. C.; Vyas, T. D.; Vyas, J. M.; Turbett, S. E.; Li, J. Z.; Lemieux, J. E.; Barczak, A. K.; Siedner, M. J.
title: Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19
date: 2022-05-26
journal: nan
DOI: 10.1101/2022.05.24.22275326
sha: 985df9f378d8012d27a067c896de1c61f3cbb5ff
doc_id: 323043
cord_uid: 14ptitsn

We enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

Nirmatrelvir-ritonavir, which inhibits the main viral protease of SARS-CoV-2, has been shown to 2 reduce hospitalization in high-risk patients with early stage, symptomatic COVID-19 infection [1] .

The US Food and Drug Administration granted emergency use authorization (EUA) status for its 4 use in December, 2021 and it is currently a preferred therapy for ambulatory individuals with 5 COVID-19 at high risk of severe disease [2] . As nirmatrelvir-ritonavir has entered into broad 6 clinical use, reports have emerged of recurrent symptoms in a subset of treated individuals who 7 had initial symptomatic improvement [3] . However, the mechanism and viral characteristics of 8 symptomatic relapse after nirmatrelvir-ritonavir therapy remain unclear. We sought to 9 characterize the virology of symptomatic rebound after nirmatrelvir-ritonavir with longitudinal 10 sampling of individuals with assessment of nasal swabs with viral load quantification, viral 11 culture, and whole genome viral sequencing.

The POSITIVES cohort is a longitudinal study of individuals with COVID-19 infection that aims 16 to characterize virologic and immunologic aspects of infection [4] [5] [6] . To better understand the 17 clinical phenomenon of symptom relapse after nirmatrelvir-ritonavir treatment, we selectively enrolled seven ambulatory individuals recently treated with nirmatrelvir-ritonavir with recurrent 19 symptoms after initial resolution. Individuals were identified through the Mass General Brigham CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Viral transport media was centrifuged for 2 hours at 21,000 x g and 4°C to pellet virions. TRIzol-28 LS™ Reagent (ThermoFisher) was then added to the pellets, and samples were subsequently 29 incubated on ice for 10 minutes. Chloroform (MilliporeSigma) was added to each sample, and 30 the resulting mixtures were then vortexed and centrifuged for 15 minutes at 21,000 x g and 4°C.

The clear aqueous layer was collected and concentrated using isopropanol precipitation. RNA 32 was washed with cold 70% ethanol before being resuspended in DEPC-treated water 33 (ThermoFisher). SARS-CoV-2 viral RNA was tested with a qPCR assay using the US CDC 34 2019 nCoV_N1 primer and probe set and quantified using a standard curve. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.24.22275326 doi: medRxiv preprint previously described [4] . We constructed sequencing libraries using the Illumina Nextera XT 52 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.24.22275326 doi: medRxiv preprint between laboratory-based rapid antigen testing and culture positivity, with no specimens that individuals with relapse after therapy holds promise as a means of signaling a safe release from 104 isolation.

Finally, we did not identify emergence of any resistance-associated polymorphisms in any of the 107 six specimens that were sequenced. Our findings add support to others that drug resistance 108 does not appear to be a significant contributor to relapse [3, 8] and suggest that nirmatrelvir-109 ritonavir may retain activity in most cases of symptom recrudescence.

Our study should be interpreted in the context of limitations. Most notably, this represents a 112 small case series so precise estimates of culture positivity, duration of viral shedding, or 113 incidence of drug resistance cannot be made. We also enrolled individuals after clinical 114 rebound, so cannot determine the incidence of this syndrome among individuals taking 115 nirmatrelvir-ritonavir treatment. Finally, we use viral culture as a proxy measure of 116 contagiousness but cannot quantify the risk of transmission for this patient population.

In summary, recurrent clinical disease after nirmatrelvir-ritonavir therapy for COVID-19 is 119 associated with high viral load and, in some cases, culturable virus. Culturable virus was 120 present for up to two weeks after completion of therapy. Consideration should be given to 121 revising public health guidelines to specifically recommend repeat testing and isolation in these 122 cases. Future work is needed to better understand the causes, clinical significance, and public 123 health consequences of symptomatic relapse after nirmatrelvir-ritonavir.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.24.22275326 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.24.22275326 doi: medRxiv preprint

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Therapeutic Management of Nonhospitalized Adults With COVID-19

Rapid Relapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. 2022

Duration of viral shedding and culture positivity with post-vaccination SARS-CoV-2 delta variant infections

Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses

Duration of viable virus shedding in SARS-CoV-2 omicron variant infection

Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay

The authors would like to thank Vamsi Thiriveedhi, Ha Eun Cho, and Seamus Carroll for assistance with sequencing. We would also like to thank the participants for their time and participation, as well as the many physicians for referral of patients to our study.

This study was supported by the Massachusetts Consortium for Pathogen Readiness (grants to Drs. Li, Lemieux, Siedner, and Barczak) and the Massachusetts General Hospital Department of Medicine (grant to Dr. Vyas). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 AI060354).

Although field-based tested is needed to confirm our findings, we found high concordance